Ado-trastuzumab emtansine

(Kadcyla®)

Kadcyla®

Drug updated on 11/13/2023

Dosage FormInjection (intravenous; 100 mg, 160 mg)
Drug ClassHER2 iInhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • • For the treatment of patients who received prior therapy for metastatic disease with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.
  • For the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

Product Monograph / Prescribing Information

Document TitleYearSource
Kadcyla (ado-trastuzumab emtansine) Prescribing Information.2022Genentech, Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis. 2023European Journal of Cancer
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis. 2023Radiotherapy and Oncology
Efficacy and safety of antibody-drug conjugates in triple-negative and HER-2 positive breast cancer: A systematic review and meta-analysis of clinical trials. 2023Breast Disease
Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis. 2023ESMO Open
Neoadjuvant treatment with HER2-targeted therapies in HER2-positive breast cancer: a systematic review and network meta-analysis.2022Cancers
Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer: a systematic review and meta-analysis.2022Journal of Cancer Research and Therapeutics
Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials.2022Expert Review of Clinical Pharmacology
Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis. 2022Cancers
Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials. 2022Expert Review of Clinical Pharmacology
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis. 2022BMC Cancer
Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and Bayesian network analysis.2021Journal of Cancer
Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis. 2021Annals of Translational Medicine
Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.2021Future Oncology
Efficacy and safety of pyrotinib versus T-DM1 in HER2+ metastatic breast cancer patients pre-treated with trastuzumab and a taxane: a Bayesian network meta-analysis.2021Frontiers in Oncology
Final clinical guidance report: trastuzumab emtansine (Kadcyla) for early breast cancer.2020CADTH
The incidence of atrial fibrillation with trastuzumab treatment: a systematic review and meta‐analysis.2018Cardiovascular Therapeutics
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update. 2018Journal of Clinical Oncology

Clinical Practice Guidelines